针对DLBCL中的表观遗传重编程及其与瘤微环境的相互作用,以获得新的治疗方法
Lili Zhou1, Wei Cheng2, Qingqing Luo1
1Department of Hematology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Jiangxi Provincial Key Laboratory of Hematological Diseases (2024SSY06052), Nanchang, Jiangxi, China.
International immunopharmacology
|June 10, 2025
概括
扩散性大B细胞淋巴瘤 (DLBCL) 治疗面临的挑战是复发性或耐药性疾病. 表观遗传改变驱动瘤进展和免疫逃避,为改善患者结果提供新的治疗点.
科学领域:
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 免疫学 免疫学 免疫学
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 是一种具有显著复发率的侵袭性非霍奇金淋巴瘤.
- 瘤微环境相互作用和表观遗传失调是DLBCL进展和免疫逃避的关键.
研究的目的:
- 审查DLBCL.的表观遗传向策略.
- 确定新组合疗法的研究方向.
- 为了在DLBCL中推进精准医学.
主要方法:
- 对基因组学,转录组学和单细胞分析的最新进展进行分析.
- 对表观遗传变化的评估 (DNA甲基化,基因组修饰,RNA编辑).
- 评估临床开发中的新兴表观遗传向疗法.
主要成果:
- 表观遗传变化在DLBCL中动态调节免疫逃避和瘤进展.
- 针对表观遗传失调的新型疗法显示出有前途.
- 恢复免疫监测是一个关键的治疗目标.
结论:
- 表观遗传策略为治疗复发/耐药DLBCL提供了一个有希望的途径.
- 需要进一步的研究来将这些发现转化为有效的组合疗法.
- 针对表观遗传机制的精准医学方法可以改善患者的治疗结果.
更多相关视频
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Tumor Immunotherapy
489
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
489


